Stockscreener 앱 받기
9.62
0.63%
0.06
전일 마감가:
$9.56
열려 있는:
$9.52
하루 거래량:
11.68M
Relative Volume:
3.28
시가총액:
$2.73B
수익:
-
순이익/손실:
$-125.04M
주가수익비율:
-11.73
EPS:
-0.82
순현금흐름:
$-122.99M
1주 성능:
+42.31%
1개월 성능:
+173.30%
6개월 성능:
+568.06%
1년 성능:
+417.20%
1일 변동 폭
$9.085
$9.87
1주일 범위
$5.89
$9.87
52주 변동 폭
$1.01
$9.87
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
3115 MERRYFIELD ROW, SAN DIEGO
ERAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
9.62 | 2.71B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
Erasca (ERAS) touches 3-year high as 4 analysts go bullish; gets 267% PT hike - MSN
Erasca Offers $7.50 Put Option, Attracting Investor Interest - Intellectia AI
Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike - Finviz
Erasca price target raised to $11 from $5 at Piper Sandler - TipRanks
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Yahoo Finance
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - PR Newswire
HC Wainwright Has Strong Estimate for Erasca FY2027 Earnings - Defense World
Winners Losers: What is AXIS Capital Holdings Limiteds debt to equity ratioAnalyst Downgrade & Fast Gain Stock Tips - baoquankhu1.vn
Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference - Yahoo Finance
Erasca Rallies Amid Acquisition Talks and Positive Price Target Revisions - StocksToTrade
Clear Street Elevates Erasca: Price Target Stands Tall at $11 - timothysykes.com
FY2027 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions - Yahoo Finance
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - Insider Monkey
Erasca stock hits 52-week high at 8.33 USD By Investing.com - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Trading Up 7.7% Following Analyst Upgrade - Defense World
Erasca (ERAS) Price Target Increased by 30.91% to 6.53 - Nasdaq
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data - TechStock²
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
Erasca (NASDAQ:ERAS) Trading Up 7.7% After Analyst Upgrade - MarketBeat
RAS buzz lifts Erasca | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83% - Finviz
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Erasca (ERAS) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year - AOL.com
ERAS: Lead RAS-targeting programs show promising early efficacy and safety, with key data expected in 2024 - TradingView — Track All Markets
Erasca stock price target raised to $11 from $6 at H.C. Wainwright - Investing.com Nigeria
ERAS Stock Update: HC Wainwright & Co. Raises Price Target to $1 - GuruFocus
HC Wainwright Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca (NASDAQ:ERAS) Hits New 52-Week High – Time to Buy? - Defense World
Erasca price target raised to $11 from $3 at Clear Street - TipRanks
Erasca (NASDAQ:ERAS) Shares Down 6.7%Here's Why - MarketBeat
Stifel raises Erasca stock price target to $10 on pipeline updates - Investing.com Canada
Erasca reports early responses with RAS-targeting cancer drug By Investing.com - Investing.com Nigeria
Erasca reports early responses with RAS-targeting cancer drug - Investing.com
Erasca Highlights Accelerated Progress in RAS-Targeted Trials - TipRanks
Erasca, Inc. Announces Clinical Progress and Milestones for RAS-Targeting Franchise - TradingView — Track All Markets
Erasca Stocks Surge Amid Merck Negotiations and AbbVie Interest - timothysykes.com
Erasca (NASDAQ:ERAS) Shares Gap Up – Should You Buy? - Defense World
Erasca (ERAS) Faces FDA Trial Pause and New Patent Win Is Its RAS Strategy Balanced? - simplywall.st
Erasca Stock Surges as Market Eyes Revolution Medicines Acquisition - StocksToTrade
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - MSN
Why Erasca Inc. stock could be next big winner2025 Price Momentum & Daily Stock Trend Watchlist - Улправда
Ebun Garner Sells 120,000 Shares of Erasca (NASDAQ:ERAS) Stock - Defense World
Erasca (NASDAQ:ERAS) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Erasca price target raised to $6 from $4 at Stifel - MSN
Erasca Stock Surges Amid Merger Talks and Positive Analyst Ratings - StocksToTrade
Erasca Inc. (ERAS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Erasca (NASDAQ:ERAS) Shares Gap UpShould You Buy? - MarketBeat
Erasca (NASDAQ:ERAS) Stock Rating Upgraded by Piper Sandler - MarketBeat
Why Erasca Inc. stock appeals to analystsEarnings Growth Report & Weekly High Potential Stock Alerts - Улправда
Risk Analysis: Why Erasca Inc stock is favored by pension fundsNew Guidance & Proven Capital Preservation Tips - Bộ Nội Vụ
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):